<- Go Home
Genentech, Inc.
Genentech, Inc. operates as a biotechnology company that discovers and develops medicines for people with diseases. It offers medicines for the areas of oncology, immunology, neuroscience, metabolism, infectious disease, and ophthalmology. The company was formerly known as Genentech Delaware, Inc. and changed its name to Genentech, Inc. in January 1987. The company was founded in 1976 and is based in South San Francisco, California with additional offices in Hillsboro, Oregon; and Vacaville, Oceanside, California. Genentech, Inc. operates as a subsidiary of Roche Holding AG.
Market Cap
$100.1B
Volume
4.6M
Cash and Equivalents
$4.5B
EBITDA
$5.7B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$11.4B
Profit Margin
85.31%
52 Week High
$99.14
52 Week Low
$66.80
Dividend
N/A
Price / Book Value
6.38
Price / Earnings
29.59
Price / Tangible Book Value
7.65
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
$5.1B
Return on Equity
24.85%
Return on Assets
15.56
Cash and Short Term Investments
$6.2B
Debt
$2.8B
Equity
$15.7B
Revenue
$13.4B
Unlevered FCF
$3.6B
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium